Skip to main content
Clinical Trials/NCT03425903
NCT03425903
Completed
Not Applicable

Clinical Research, Randomized, Open, Unmasked, Controlled, Cross-group, Active-treatment, to Evaluate the Clinical Efficacy of Whole Body Cryotherapy (WBC) in the Cryosense TCT Cabin for the Treatment of Fibromyalgia

Tecnología e Innovación Médico Estética S.L.1 site in 1 country60 target enrollmentNovember 16, 2016
ConditionsFibromyalgia

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Fibromyalgia
Sponsor
Tecnología e Innovación Médico Estética S.L.
Enrollment
60
Locations
1
Primary Endpoint
Fibromyalgia Impact Questionnaire (FIQ)
Status
Completed
Last Updated
8 years ago

Overview

Brief Summary

The aim of this study is to evaluate the effectiveness of an intervention with sessions of 3 minutes of whole body cryotherapy (WBC) in the Cryosense cabin. Measurement period time: 8 weeks.

Detailed Description

The aim of this study is to evaluate the effectiveness of an intervention with sessions of 3 minutes of whole body cryotherapy (WBC) in the Cryosense cabin, on the main clinical manifestations of patients with Fibromyalgia (FM). A randomized, open and crossed 8-week clinical trial comparing a WBC intervention with the waiting list control group. Patients diagnosed with FM according to ACR 2010 criteria, in treatment and regular follow-up recruited consecutively. Two groups were made, one of intervention and one of waiting list which served as control during the first phase. At the end of the first phase, and after a week of washout, the groups crossed and went on to carry out the second phase following the opposite intervention. The pharmacological treatment was not modified during the entire study. Trial endpoints were changed in pain after 2 and 4 weeks, measured by a visual analogue scale (VAS) and burden of disease, evaluated by the Fibromyalgia Impact Questionnaire(FIQ).

Registry
clinicaltrials.gov
Start Date
November 16, 2016
End Date
June 9, 2017
Last Updated
8 years ago
Study Type
Interventional
Study Design
Crossover
Sex
All

Investigators

Sponsor
Tecnología e Innovación Médico Estética S.L.
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Age between 25 and 80 years old
  • Diagnosis of Fibromyalgia according to ACR criteria
  • More than 1 year from diagnosis
  • Lack of response or partial response to previous treatment
  • In case of women,commitment not to get pregnant during the study.

Exclusion Criteria

  • Patiens with cardiovascular or psychiatric comorbidity
  • Cold intolerance
  • Changes in pharmacological treatment during the study
  • Body temperature over 37,5ºC

Outcomes

Primary Outcomes

Fibromyalgia Impact Questionnaire (FIQ)

Time Frame: 8 weeks

This instrument composed of 10 items, measures physical functioning, work status (missed days of work and job difficulty), depression, anxiety, morning tiredness, pain, stiffness, fatigue, and well-being over the past week.

Secondary Outcomes

  • Combined Index of Severity of Fibromyalgia (ICAF)(8 weeks)
  • General health questionnaire (SF36)(8 weeks)
  • Pain intensity measure. Visual Analogyc scale (VAS)(8 weeks)

Study Sites (1)

Loading locations...

Similar Trials